Clinical Trial Update: Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tislelizumab plus anlotinib as maintenance therapy after first-line chemotherapy in extensive-stage small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Small Cell Lung Carcinoma | Phase 2 | Status: UNKNOWN